24/7 Market News Snapshot 13 August, 2025 – Ovid Therapeutics Inc. Common Stock (NASDAQ:OVID)
DENVER, Colo., 13 August, 2025 (www.247marketnews.com) – (NASDAQ:OVID) are discussed in this article.
Ovid Therapeutics Inc. (NASDAQ:OVID) has demonstrated remarkable growth, with its stock price climbing to $0.736, reflecting an impressive increase of 34.55% following a previous close of $0.547. This surge has been fueled by significant trading activity, totaling 5.15 million shares, as investor enthusiasm heightens around the company’s advancing clinical pipeline amid a competitive biotech landscape.
As Ovid Therapeutics positions itself for substantial advancements, it has highlighted key upcoming milestones. The ongoing Phase 1 study of OV329, an innovative GABA-aminotransferase (GABA-AT) inhibitor targeting treatment-resistant seizures, is expected to deliver topline safety, tolerability, and biomarker results by late Q3 2025. With the goal of providing a safer alternative to existing therapies, OV329’s development underscores Ovid’s commitment to addressing critical patient needs in neurological conditions.
In parallel, significant strides are being made in Ovid’s KCC2 program, notably with OV350, the first KCC2 direct activator. Initial safety and tolerability data from this study are anticipated by Q4 2025. The company is also advancing the IND-enabling package for OV4071, its first oral KCC2 candidate, with plans for a Phase 1/1b trial to commence in Q2 2026.
Furthermore, Ovid has secured a $7.0 million royalty monetization agreement with Immedica Pharma AB, which will bolster its financial resources and operational runway. As of June 30, 2025, Ovid reported a cash position of $38.3 million, expected to sustain the ongoing clinical programs through the first half of 2026. The company’s revenue from royalty agreements reached $6.3 million in the second quarter, marking a notable increase from the prior year and reflecting prudent management of operating expenses.
Ovid Therapeutics is steadfast in its mission to innovate therapies that respond to significant unmet medical needs, reinforcing its position for future growth and impactful contributions within the biopharmaceutical sector.